Soligenix Inc. unveils pipeline progress and rare disease treatment strategies in new corporate presentation

Reuters11-25

Soligenix Inc. unveils pipeline progress and rare disease treatment strategies in new corporate presentation

Soligenix Inc. has released a corporate presentation outlining updates across its pipeline for rare disease treatments and public health solutions. The company highlighted progress in its Specialized BioTherapeutics segment, including the ongoing Phase 2a clinical study of SGX302 for mild-to-moderate psoriasis, with clinical success observed in two of four patients in Cohort 2. The presentation also noted the completion of a Phase 2a proof-of-concept study for SGX945 in treating aphthous ulcers in Behçet's Disease, demonstrating biological efficacy and safety. Within its Public Health Solutions segment, Soligenix reported continued development of its vaccine candidates for ricin toxin, filoviruses such as Ebola and Marburg, and COVID-19, supported by ongoing government funding and collaborations. The pipeline includes multiple fast track and orphan designated products, with several candidates advancing through late-stage clinical studies and regulatory discussions. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Soligenix Inc. published the original content used to generate this news brief on November 24, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2586491196?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-25 01:52","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2586491196","market":"nz","top_or_hot":-1,"title":"Soligenix Inc. unveils pipeline progress and rare disease treatment strategies in new corporate presentation","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Soligenix Inc. unveils pipeline progress and rare disease treatment strategies in new corporate presentation\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Soligenix Inc. has released a corporate presentation outlining updates across its pipeline for rare disease treatments and public health solutions. The company highlighted progress in its Specialized BioTherapeutics segment, including the ongoing Phase 2a clinical study of SGX302 for mild-to-moderate psoriasis, with clinical success observed in two of four patients in Cohort 2. The presentation also noted the completion of a Phase 2a proof-of-concept study for SGX945 in treating aphthous ulcers in Behçet's Disease, demonstrating biological efficacy and safety. Within its Public Health Solutions segment, Soligenix reported continued development of its vaccine candidates for ricin toxin, filoviruses such as Ebola and Marburg, and COVID-19, supported by ongoing government funding and collaborations. The pipeline includes multiple fast track and orphan designated products, with several candidates advancing through late-stage clinical studies and regulatory discussions. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Soligenix Inc. published the original content used to generate this news brief on November 24, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Soligenix Inc. unveils pipeline progress and rare disease treatment strategies in new corporate presentation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSoligenix Inc. unveils pipeline progress and rare disease treatment strategies in new corporate presentation\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-25 01:52</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Soligenix Inc. unveils pipeline progress and rare disease treatment strategies in new corporate presentation\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Soligenix Inc. has released a corporate presentation outlining updates across its pipeline for rare disease treatments and public health solutions. The company highlighted progress in its Specialized BioTherapeutics segment, including the ongoing Phase 2a clinical study of SGX302 for mild-to-moderate psoriasis, with clinical success observed in two of four patients in Cohort 2. The presentation also noted the completion of a Phase 2a proof-of-concept study for SGX945 in treating aphthous ulcers in Behçet's Disease, demonstrating biological efficacy and safety. Within its Public Health Solutions segment, Soligenix reported continued development of its vaccine candidates for ricin toxin, filoviruses such as Ebola and Marburg, and COVID-19, supported by ongoing government funding and collaborations. The pipeline includes multiple fast track and orphan designated products, with several candidates advancing through late-stage clinical studies and regulatory discussions. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Soligenix Inc. published the original content used to generate this news brief on November 24, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SNGX","symbol_name":"Soligenix, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251124:nNDL5vYRK0:1","article_id":"2586491196","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2586491196","pubTimestamp":1764006762,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Soligenix Inc. has released a corporate presentation outlining updates across its pipeline for rare disease treatments and public health solutions. The company highlighted progress in its Specialized BioTherapeutics segment, including the ongoing Phase 2a clinical study of SGX302 for mild-to-moderate psoriasis, with clinical success observed in two of four patients in Cohort 2. The presentation also noted the completion of a Phase 2a proof-of-concept study for SGX945 in treating aphthous ulcers in Behet's Disease, demonstrating biological efficacy and safety. Within its Public Health Solutions segment, Soligenix reported continued development of its vaccine candidates for ricin toxin, filoviruses such as Ebola and Marburg, and COVID-19, supported by ongoing government funding and collaborations. The pipeline includes multiple fast track and orphan designated products, with several candidates advancing through late-stage clinical studies and regulatory discussions. You can access the fu","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SNGX":"Soligenix, Inc.","BK4139":"生物科技"},"translate_title":"Soligenix Inc.在新的公司演示中公布了管道进展和罕见疾病治疗策略","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SNGX":0.9},"content_text":"Soligenix Inc. unveils pipeline progress and rare disease treatment strategies in new corporate presentation\n    \n\n        Soligenix Inc. has released a corporate presentation outlining updates across its pipeline for rare disease treatments and public health solutions. The company highlighted progress in its Specialized BioTherapeutics segment, including the ongoing Phase 2a clinical study of SGX302 for mild-to-moderate psoriasis, with clinical success observed in two of four patients in Cohort 2. The presentation also noted the completion of a Phase 2a proof-of-concept study for SGX945 in treating aphthous ulcers in Behçet's Disease, demonstrating biological efficacy and safety. Within its Public Health Solutions segment, Soligenix reported continued development of its vaccine candidates for ricin toxin, filoviruses such as Ebola and Marburg, and COVID-19, supported by ongoing government funding and collaborations. The pipeline includes multiple fast track and orphan designated products, with several candidates advancing through late-stage clinical studies and regulatory discussions. You can access the full presentation through the link below.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Soligenix Inc. published the original content used to generate this news brief on November 24, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2586491196","isCrawlerRequest":true}